ALAMEDA, Calif. - Vivani Medical, Inc. (NASDAQ: VANI), a biopharmaceutical company focused on long-term drug implants, announced the appointment of Daniel Bradbury to its Board of Directors. Bradbury, a seasoned professional with a history at Amylin Pharmaceuticals, will also join the Audit Committee of the board.
Bradbury's tenure at Amylin Pharmaceuticals culminated in the approval of Bydureon®, the first once-weekly GLP-1 receptor agonist, in 2012. His experience is expected to be beneficial as Vivani advances its GLP-1 implants for obesity and type 2 diabetes treatment. The company's lead programs, NPM-115 and NPM-119, are six-month exenatide-based implants in development for chronic weight management and type 2 diabetes, respectively.
Vivani's President and CEO, Adam Mendelsohn, Ph.D., highlighted Bradbury's invaluable advice since 2017 and anticipates that his expertise will be pivotal for the company's focus on GLP-1 implants. Bradbury's past roles include leadership positions at Amylin, which was acquired by Bristol-Myers Squibb (NYSE:BMY) for $7.1 billion in August 2012, and marketing and sales at SmithKline Beecham Pharmaceuticals. He also serves on the boards of several other companies and non-profit organizations.
The company is developing these implants through its proprietary NanoPortal™ platform with the aim of improving medication adherence and tolerability. Medication non-adherence, a significant issue in the U.S., contributes to avoidable healthcare costs and preventable deaths annually.
Vivani's subsidiary, Cortigent, is working on neurostimulation systems, including Orion®, which aims to provide artificial vision for the blind, and a system to aid arm and hand function recovery post-stroke. The company is exploring strategic options for Cortigent's technology.
This announcement is based on a press release statement and contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These statements are subject to uncertainties and risks, and actual results may differ. The company does not undertake any obligation to update forward-looking statements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.